StocksMedium•9 October 2026•
1 min read
FDA Approves Asahi Kasei Drug for Persistent Herpes Treatment
Key Facts
1The US FDA has approved a new drug from Asahi Kasei Corporation designed to treat persistent herpes infections.
The US Food and Drug Administration (FDA) approved a new drug from Asahi Kasei Corporation designed to treat persistent herpes infections. Investing.com reported that the approval follows a regulatory review of the drug's efficacy and safety in treating chronic cases of the virus.
Asahi Kasei stock, trading under the ticker 3407.T, closed at 1650.5 JPY on October 8, 2026. The instrument reached a day high of 1659 JPY and a low of 1640 JPY during that session, prior to the announcement of the regulatory milestone which is expected to support the company's pharmaceutical market expansion.